Competition and Price Declines in the Research-Use Human Cultured Tissue Market
First written in FY2016. 1 of 3 entries say "Restated". Latest entry: FY2024.
0 other companies' latest entry also says "Dropped".
- FY2024DroppedAnnual reportThe FY2024 business and other risks section does not identify competition and price decline risks specific to the research-use human cultured tissue market as a separate item.
- FY2020RestatedAnnual report
「As part of its research and development support business, the company sells the LabCyte series of research-use human cultured tissues to manufacturers of cosmetics, pharmaceuticals, food products, chemicals, daily necessities and agricultural chemicals, as well as contract safety testing organizations. Several competing companies operate in this market.」
The company continues to disclose the risk of lower profitability in the LabCyte market due to multiple competitors, stagnant sales volume and price declines. - FY2016First statedAnnual report
「The company entered the market later than its competitors, and several competing companies operate in the market. Accordingly, profitability may decline because intensifying competition may constrain sales volume growth, excessive competition may cause selling prices to fall, and expanding sales may require a larger sales organization and higher expenses.」
For LabCyte, the company identifies late market entry, competition, price declines and higher selling expenses as risks to profitability.